Présentation de l'entreprise
Global Medical REIT Inc. operates as a net-lease real estate investment trust focused on the acquisition and leasing of healthcare facilities to physician groups, regional systems, and national healthcare networks. This business model places the company within the Real Estate sector, specifically the REIT - Healthcare Facilities industry, where it functions as an intermediary between property owners and medical service providers. The organization maintains a significant market capitalization of $979.78 million and generates an annual revenue of $144.83 million, supported by a workforce of 26 employees. These financial metrics indicate that the company holds a substantial asset base relative to its lean operational staff, suggesting a capital-intensive business model where value is derived primarily from real estate holdings rather than labor intensity. The market cap of nearly one billion dollars reflects the aggregate market valuation of its real estate portfolio, while the revenue figure demonstrates the steady cash flow generated from long-term leases within the healthcare infrastructure space.
Santé financière
The company reports a trailing twelve-month revenue of $144.83 million against a net income loss of $-3,324,000, revealing a cost structure where operating expenses or interest costs exceed the bottom-line earnings despite strong top-line performance. However, the entity maintains a robust EBITDA of $87.53 million, which serves as a critical indicator of operational cash generation before financing and non-cash charges. Free cash flow stands at $66.02 million, a figure that highlights the company's financial flexibility to service its obligations and potentially fund future acquisitions without relying on external equity issuance. The margin profile is distinctive, featuring a gross margin of 99.9% typical of net-lease structures, an operating margin of 24.5%, and a profit margin of 1.7%. The disparity between the high gross margin and the lower profit margin indicates significant operating leverage or interest expenses impacting the final profitability. Liquidity is supported by $14.59 million in cash on hand, yet this is offset by total debt of $723.14 million, resulting in a debt-to-equity ratio of 142.96% that signifies a highly leveraged balance sheet. Short-term liquidity appears manageable with a current ratio of 1.91, suggesting current assets are nearly double current liabilities. Return on equity is recorded at 0.4% while return on assets sits at 1.7%, metrics that collectively indicate limited management effectiveness in generating returns on the substantial capital invested in the portfolio relative to the leverage burden.
Évaluation de la valorisation
Valuation multiples present a complex picture, with a trailing P/E ratio listed as N/A due to the negative net income, while the forward P/E stands at 299.83, implying the market prices the stock based on anticipated future earnings normalization rather than current profitability. The price-to-book ratio of 1.18 suggests the market values the company's equity slightly above its book value, indicating a modest premium over the tangible assets recorded on the balance sheet. Alternative valuation metrics provide further context, with a price-to-sales ratio of 6.77 and an EV/EBITDA of 14.70, suggesting investors are willing to pay a significant multiple for sales and a moderate multiple for operating cash flow. Price volatility is framed by a 52-week high of $45.75 and a low of $29.05; without a specific current price provided in the facts, the relative trading position cannot be calculated, but the range defines the recent trading envelope. The stock exhibits a beta of 1.20, which indicates that the asset price is 20% more volatile than the broader market, reflecting the heightened sensitivity of healthcare real estate REITs to interest rate fluctuations and sector-specific demand cycles.
Growth & Income
Revenue growth is accelerating at an 8.6% year-over-year rate, whereas earnings growth is N/A due to the current period losses, implying that revenue expansion is not yet translating into bottom-line profitability at this stage of the company's cycle. For dividend investors, the company offers a dividend yield of 8.3%, but this is supported by a payout ratio of 1114.3%, which is unsustainable given the negative net income and indicates that dividends are being paid from cash flows rather than retained earnings. This high payout ratio necessitates careful scrutiny regarding the long-term sustainability of the distribution in the absence of consistent net income growth. The overall growth and income profile presents a high-yield opportunity tempered by significant leverage and a lack of current earnings growth, creating a distinct risk-reward dynamic for income-focused strategies.